You are here

  • Home
  • Archive
  • Volume 104, Issue 9
  • Changes in neovascular activity following fixed dosing with an anti-vascular endothelial growth factor agent over 52 weeks in the phase III VIEW 1 and VIEW 2 studies

Article metrics

Article menu
Download PDFPDF
Clinical science
Changes in neovascular activity following fixed dosing with an anti-vascular endothelial growth factor agent over 52 weeks in the phase III VIEW 1 and VIEW 2 studies

 

Online download statistics by month:

Online download statistics by month: December 2019 to March 2024

AbstractFullPdf
Dec 20192094894858
Jan 2020232412831256
Feb 2020916444432
Mar 20201273922
Apr 2020105228
May 20201182614
Jun 2020127168
Jul 2020180112
Aug 20204022913
Sep 20204364723
Oct 2020822812
Nov 20205398
Dec 2020114106
Jan 20218264
Feb 20213986
Mar 20218264
Apr 20218233
May 2021843
Jun 2021765
Jul 2021141413
Aug 2021776
Sep 2021657
Oct 20214353
Nov 20217493
Dec 20217673
Jan 20227472
Feb 20227164
Mar 20226986
Apr 20228063
May 202219261
Jun 202213883
Jul 202296104
Aug 2022197113
Sep 202214864
Oct 2022156382
Nov 2022187126
Dec 202213042
Jan 20236764
Feb 202319132
Mar 20237330
Apr 20236551
May 20234240
Jun 20235530
Jul 20234263
Aug 20231640
Sep 20236253
Oct 20234510
Nov 20237064
Dec 20236722
Jan 202410053
Feb 202421923
Mar 20245922
Total1030931172789